Catalent Biosimilars Manufacturing Update

Biosimilar News  •  Deal Watch
  • Yesterday, Catalent Pharma Solutions announced that it has broken ground for a 22,000 square foot extension of its biologics manufacturing facility in Madison, Wisconsin.  According to the press release, following completion of the expansion, Catalent will be able to provide biologics for late-stage clinical and commercial purposes.
  • In addition, last week, Catalent announced that it will provide fill-finish production services for Samsung Bioepis’ SB4.  SB4 is a biosimilar of Amgen’s Enbrel® (etanercept).

Stay tuned to Big Molecule Watch for continuing developments.

Download PDF

Comments are closed.